Phase 3 MAGNITUDE study: First results of niraparib (NIRA) with abiraterone acetate and prednisone (AAP) as first-line therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with and without homologous recombination repair (HRR) gene alterations.

MAGNITUDE study of niraparib + abiraterone/prednisone. reasonable option for men with HRR deficient prostate cancer who were otherwise eligible for PARP inhibitors.

Read the full article here

Related Articles